LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its...
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb....
Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11%...
PharmaJet presentation will highlight the results of recent immunization studies using needle-free intradermal (ID) delivery for polio immunization campaigns. Data...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News...
Burlington, Ontario--(Newsfile Corp. - February 18, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced...
Nomination could expedite GC376 availability for veterinariansBlack market FIP treatments shown to be unpredictable and dangerousOther organizations are encouraged to...
HYDERABAD, India, Feb. 17, 2025 /PRNewswire/ -- Foxx Life Sciences is delighted to announce the successful completion of its Open...
Gold-standard accreditation underscores Emmes Group's commitment to secure and data-rich trials for biotech and pharma partners ROCKVILLE, Md., Feb. 12,...
- Founded by Professors Omar Abudayyeh, Jonathan Gootenberg, and Patrick Hsu leveraging novel AI models and technologies for designing, building,...
ATHENS, Ga., Feb. 12, 2025 /PRNewswire/ -- Dalan Animal Health, a global leader in bioscience innovation, today announced a major breakthrough...
Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety...
The Greatest Celebration of American Innovation will be held in Washington, D.C., on May 7-8 NORTH CANTON, Ohio, Feb. 11,...
Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology...
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of...
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the...
Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an...
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing...
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- --...
– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 – NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE)...